Phospho-TEK (Y1108) Antibody

What is Phospho-TEK (Y1108) Antibody and what does it specifically recognize?

Phospho-TEK (Y1108) antibody specifically recognizes the tyrosine residue at position 1108 of the TEK (Tie-2) receptor when it is phosphorylated. This antibody is designed to detect a specific post-translational modification that occurs during Tie-2 receptor activation. The immunogen used for antibody production is a synthetic phosphopeptide derived from human Tie-2 around the phosphorylation site of Tyrosine 1108. The antibody has been specifically validated to ensure no cross-reactivity with other proteins, making it a precise tool for studying Tie-2 phosphorylation at this specific residue.

How does Phospho-TEK (Y1108) differ from other phospho-specific TEK antibodies?

Phospho-TEK (Y1108) antibody differs from other phospho-specific TEK antibodies in the specific tyrosine residue it recognizes. For example, the Phospho-Tie-2 (Y1102/Y1100) antibody recognizes different phosphorylation sites (tyrosine 1102 in human or tyrosine 1100 in mouse). Each phosphorylation site on the TEK receptor may have distinct functional roles in signal transduction. The Y1108 site has specific significance in TEK receptor activation and downstream signaling, and using an antibody specific to this phosphorylation site allows researchers to investigate site-specific receptor activation and signaling dynamics.

What species reactivity does the Phospho-TEK (Y1108) antibody demonstrate?

The Phospho-TEK (Y1108) antibody demonstrates reactivity with Human, Mouse, and Rat species. This cross-species reactivity is particularly valuable for comparative studies and translational research, allowing consistent experimental approaches across different model systems. The conservation of this phosphorylation site across multiple species suggests its functional importance in TEK signaling.

What are the validated applications for Phospho-TEK (Y1108) antibody?

The Phospho-TEK (Y1108) antibody has been validated primarily for Western Blot (WB) applications. For optimal results in WB applications, the suggested dilution range is 1:500-1:2000. While Western blotting is the principal validated application, researchers may explore its utility in other applications such as immunohistochemistry (IHC) or immunofluorescence (IF), though these would require additional validation and optimization for reliable results.

What is the optimal protocol for Western blot analysis using Phospho-TEK (Y1108) antibody?

For Western blot analysis using Phospho-TEK (Y1108) antibody, the following protocol is recommended:

• Prepare cell/tissue lysates under reducing conditions

• Separate proteins by SDS-PAGE and transfer to a PVDF membrane

• Block the membrane with appropriate blocking buffer

• Dilute the Phospho-TEK (Y1108) antibody to 1:500-1:2000 in antibody dilution buffer

• Incubate the membrane with diluted primary antibody overnight at 4°C

• Wash the membrane 3-5 times with wash buffer

• Incubate with HRP-conjugated secondary antibody (anti-rabbit IgG)

• Wash again 3-5 times

• Develop using chemiluminescent substrate

• Image the membrane

TEK/Tie-2 has a molecular weight of approximately 140-150 kDa, so the phosphorylated form should be detected at this size range. For positive control, lysates from cells treated with angiopoietin-1 (a Tie-2 ligand) can be used, as demonstrated in similar antibodies targeting Tie-2 phosphorylation.

How should researchers optimize fixation conditions for immunohistochemistry with Phospho-TEK (Y1108) antibody?

While the Phospho-TEK (Y1108) antibody's primary validated application is Western blotting, researchers interested in IHC applications can take guidance from protocols used with similar phospho-Tie-2 antibodies. For paraffin-embedded tissue sections, an immersion fixation protocol is recommended. Based on similar antibodies targeting phosphorylated Tie-2:

• Fix tissues in 10% neutral buffered formalin

• Process and embed in paraffin following standard protocols

• Section tissues at 4-6 μm thickness

• Deparaffinize and rehydrate sections

• Perform antigen retrieval (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Apply protein block to reduce non-specific binding

• Incubate with Phospho-TEK (Y1108) antibody at 10-15 μg/mL overnight at 4°C

• Wash and apply HRP-conjugated secondary antibody

• Develop with DAB substrate and counterstain with hematoxylin

Phospho-epitopes can be sensitive to fixation conditions, so optimization of fixation time and antigen retrieval methods may be necessary to maintain phospho-epitope integrity.

How can Phospho-TEK (Y1108) antibody be used to study angiogenesis pathways?

Phospho-TEK (Y1108) antibody can be used to study angiogenesis pathways by monitoring the activation state of the Tie-2 receptor in response to various stimuli. Researchers can design experiments to:

• Assess Tie-2 activation in response to angiopoietin treatment (Ang1, Ang2, Ang4)

• Study the temporal dynamics of Tie-2 phosphorylation during angiogenic processes

• Investigate cross-talk between Tie-2 and other angiogenic pathways (e.g., VEGF signaling)

• Evaluate the effects of therapeutic compounds on Tie-2 signaling

• Compare Tie-2 activation in normal versus pathological angiogenesis

For such studies, researchers typically treat endothelial cells with angiopoietins or other factors, collect lysates at various time points, and perform Western blot analysis with the Phospho-TEK (Y1108) antibody. The degree of phosphorylation at Y1108 serves as a quantitative measure of receptor activation.

What strategies can be employed to integrate Phospho-TEK (Y1108) antibody data into phosphoproteomic analyses?

To integrate Phospho-TEK (Y1108) antibody data into comprehensive phosphoproteomic analyses, researchers can employ several strategies:

• Complementary approaches: Combine targeted Western blot analysis using Phospho-TEK (Y1108) antibody with mass spectrometry-based phosphoproteomics for broader pathway analysis.

• Computational integration: Utilize specialized software like PhosR to process and analyze phosphoproteomic data alongside targeted phospho-antibody results:

  • Create a PhosphoExperiment object to store quantification data

  • Perform filtering, imputation, and normalization of data

  • Identify differentially phosphorylated sites between conditions

  • Infer kinase activities and construct signalomes that include Tie-2 signaling

• Validation studies: Use Phospho-TEK (Y1108) antibody to validate phosphorylation events identified in large-scale phosphoproteomic screens.

• Temporal dynamics: Compare the kinetics of Y1108 phosphorylation with other phosphorylation events to establish signaling hierarchies.

How can researchers distinguish between specific phosphorylation sites (Y1108 vs Y1102/Y1100) on TEK and their functional implications?

Distinguishing between different phosphorylation sites on TEK and understanding their functional implications requires a multi-faceted approach:

• Site-specific antibodies: Use Phospho-TEK (Y1108) antibody alongside antibodies targeting other phosphorylation sites (e.g., Y1102/Y1100) to compare phosphorylation patterns under various conditions.

• Mutational analysis: Generate TEK constructs with specific tyrosine-to-phenylalanine mutations (Y1108F, Y1102F, Y1100F) to abolish phosphorylation at individual sites and assess the functional consequences.

• Phosphorylation kinetics: Perform time-course experiments to determine the temporal sequence of phosphorylation at different sites following receptor activation.

• Downstream signaling: Analyze how inhibition of phosphorylation at specific sites affects distinct downstream signaling pathways using both phospho-specific antibodies and pathway-specific readouts.

• Structural biology: Consider how phosphorylation at each site might alter receptor conformation and protein-protein interactions.

What are the critical storage and handling considerations for maintaining Phospho-TEK (Y1108) antibody activity?

To maintain optimal Phospho-TEK (Y1108) antibody activity, follow these storage and handling guidelines:

• Store the antibody at -20°C for long-term storage (up to one year).

• For frequent use and short-term storage (up to one month), the antibody can be kept at 4°C.

• Avoid repeated freeze-thaw cycles, which can degrade antibody quality and reduce binding efficiency.

• The antibody is formulated as Rabbit IgG at 1mg/ml in PBS with 0.02% sodium azide and 50% glycerol at pH 7.2, which helps maintain stability.

• When working with the antibody, maintain cold chain conditions whenever possible.

• Centrifuge the antibody vial briefly before opening to ensure collection of all material.

• Prepare working dilutions fresh before use for optimal results.

• Handle with appropriate safety precautions due to the presence of sodium azide in the formulation.

What are common sources of false positives/negatives when using Phospho-TEK (Y1108) antibody, and how can they be mitigated?

Common sources of false results when using Phospho-TEK (Y1108) antibody include:

To ensure reliable results, always include both positive controls (cells/tissues known to express phosphorylated TEK) and negative controls (samples treated with phosphatase or unstimulated samples).

How can researchers quantitatively analyze Phospho-TEK (Y1108) signals in relation to total TEK protein levels?

For quantitative analysis of Phospho-TEK (Y1108) in relation to total TEK protein levels, researchers should:

• Perform parallel Western blots: Run identical samples on two gels - one for probing with Phospho-TEK (Y1108) antibody and another for probing with a total TEK antibody.

• Strip and reprobe method:

  • Probe first with Phospho-TEK (Y1108) antibody

  • Document results

  • Strip the membrane using a commercial stripping buffer

  • Confirm complete stripping by incubating with secondary antibody and developing

  • Reprobe with total TEK antibody

  • Document results

• Quantification approach:

  • Use densitometry software to quantify band intensities

  • Calculate the ratio of phospho-TEK to total TEK

  • Normalize this ratio to control samples

  • Present data as "fold change in phosphorylation" relative to control

• Data presentation:

  • Western blot images showing both phospho-TEK and total TEK

  • Quantification graph showing phospho-TEK/total TEK ratios

  • Statistical analysis of replicate experiments

This approach controls for variations in total protein expression or loading differences between samples, providing a more accurate assessment of phosphorylation status.

How should researchers design experiments to study the temporal dynamics of TEK phosphorylation at Y1108?

To study temporal dynamics of TEK phosphorylation at Y1108, researchers should design time-course experiments with the following considerations:

• Stimulation protocol:

  • Select appropriate TEK activators (e.g., Angiopoietin-1 at 600 ng/mL)

  • Prepare multiple identical culture plates/dishes

  • Stimulate cells for varying durations (e.g., 0, 1, 5, 15, 30, 60, 120 minutes)

  • Include both very early (seconds to minutes) and later (hours) time points

• Sample collection:

  • Rapidly lyse cells at each time point

  • Include phosphatase inhibitors in lysis buffer

  • Process all samples identically

  • Consider snap-freezing samples for batch processing

• Analysis methods:

  • Western blot with Phospho-TEK (Y1108) antibody

  • Normalize to total TEK levels

  • Plot phosphorylation intensity versus time

  • Consider mathematical modeling of activation/deactivation kinetics

• Controls:

  • Include unstimulated controls at multiple time points

  • Consider inhibitor controls that block upstream kinases

  • Include phosphatase-treated samples as negative controls

This approach will generate high-resolution temporal data on Y1108 phosphorylation dynamics, providing insights into activation kinetics and signaling duration.

What considerations are important when correlating Phospho-TEK (Y1108) data with functional cellular responses?

When correlating Phospho-TEK (Y1108) phosphorylation data with functional cellular responses, researchers should consider:

• Temporal relationship:

  • Determine whether phosphorylation precedes, coincides with, or follows cellular responses

  • Account for signal amplification and time delays in downstream pathways

• Dose-response relationship:

  • Establish if the degree of Y1108 phosphorylation correlates with the magnitude of cellular response

  • Generate dose-response curves for both phosphorylation and functional readouts

• Causality assessment:

  • Use pharmacological inhibitors to block Tie-2 activation

  • Employ Y1108F mutants to specifically prevent phosphorylation at this site

  • Utilize RNA interference to reduce TEK expression

  • Compare results across these different approaches

• Pathway specificity:

  • Determine whether other pathways contribute to the observed cellular response

  • Assess phosphorylation of other Tie-2 residues concurrently

  • Evaluate activation of parallel signaling pathways

• Cellular context:

  • Compare results across different cell types

  • Consider the influence of cell confluency, passage number, and culture conditions

  • Evaluate the effects of extracellular matrix components

By addressing these considerations, researchers can establish robust correlations between Y1108 phosphorylation and specific biological outcomes.

How can Phospho-TEK (Y1108) antibody data be integrated into computational models of angiogenic signaling networks?

Integrating Phospho-TEK (Y1108) antibody data into computational models of angiogenic signaling requires several sophisticated approaches:

• Data preprocessing:

  • Normalize phosphorylation data using techniques like median scaling

  • Apply appropriate filtering and imputation methods for missing values

  • Transform data to appropriate scale for computational modeling

• Network construction:

  • Position Tie-2 Y1108 phosphorylation within known signaling networks

  • Define edges (connections) based on literature evidence and experimental data

  • Assign directionality and weights to connections based on quantitative measurements

• Dynamic modeling approaches:

  • Ordinary differential equations (ODEs) to model temporal dynamics

  • Boolean networks for qualitative state transitions

  • Bayesian networks to capture probabilistic relationships

  • Agent-based models for spatial aspects of angiogenesis

• Integration with other datasets:

  • Combine with transcriptomic data to connect signaling to gene expression

  • Incorporate proteomic and metabolomic data for multi-omics integration

  • Use tools like PhosR for comprehensive phosphoproteomic data analysis

  • Create a PhosphoExperiment object to facilitate data management and analysis

• Validation and refinement:

  • Use independent experimental datasets to validate model predictions

  • Perform sensitivity analysis to identify critical parameters

  • Iteratively refine the model based on new experimental evidence

By implementing these approaches, researchers can create predictive models that incorporate Y1108 phosphorylation data into a systems-level understanding of angiogenic signaling networks.

How does phosphorylation at Y1108 compare with other key phosphorylation sites on TEK in terms of biological significance?

Phosphorylation at Y1108 on TEK has distinct biological significance compared to other phosphorylation sites:

Understanding these distinctions requires parallel analysis with antibodies specific to different phosphorylation sites, combined with functional studies using site-specific mutations.

What are the key experimental considerations when using Phospho-TEK (Y1108) antibody in different model systems?

When using Phospho-TEK (Y1108) antibody across different model systems, researchers should consider:

• Species-specific optimization:

  • While the antibody reacts with human, mouse, and rat TEK, sensitivity may vary

  • Optimize antibody concentration for each species

  • Consider species-specific positive controls

• Cell type considerations:

  • Endothelial cells typically express high levels of TEK

  • Non-endothelial cells may require enrichment techniques or higher antibody concentrations

  • Primary cells versus cell lines may show different TEK expression levels and phosphorylation patterns

• In vitro versus in vivo samples:

  • Cell culture lysates typically yield cleaner results than tissue lysates

  • Tissue samples require effective extraction methods to preserve phospho-epitopes

  • Perfusion of animals before tissue collection may reduce blood contamination

• Model-specific stimulation protocols:

  • In vitro: controlled application of angiopoietins (typically 600 ng/mL)

  • In vivo: consider tissue-specific delivery methods or transgenic approaches

  • Ex vivo: rapid processing is crucial to preserve phosphorylation status

• Sample preparation adjustments:

  • Different lysis buffers may be optimal for different sample types

  • Phosphatase inhibitor cocktails may need adjustment based on model system

  • Tissue homogenization methods should be optimized to maintain epitope integrity

These considerations ensure reliable and comparable results across different experimental models and systems.

How can researchers validate the specificity and sensitivity of Phospho-TEK (Y1108) antibody in their experimental system?

To validate the specificity and sensitivity of Phospho-TEK (Y1108) antibody in a particular experimental system, researchers should:

• Positive control validation:

  • Treat cells with a known TEK activator (e.g., Angiopoietin-1 at 600 ng/mL for 5 minutes)

  • Confirm increased signal in Western blot following stimulation

  • The expected band should appear at approximately 140-150 kDa

• Negative control validation:

  • Include untreated/unstimulated samples

  • Treat stimulated samples with phosphatase to remove phosphorylation

  • Use TEK-knockout or TEK-depleted (siRNA) cells

  • Pre-block antibody with immunizing phosphopeptide

• Specificity tests:

  • Compare with other phospho-TEK antibodies targeting different sites

  • Perform peptide competition assays with phosphorylated and non-phosphorylated peptides

  • Test selectivity using cells expressing Y1108F mutant TEK

• Sensitivity assessment:

  • Create a dilution series of stimulated cell lysates

  • Determine the lower limit of detection

  • Compare with other detection methods if available

• Reproducibility evaluation:

  • Perform multiple independent experiments

  • Calculate coefficient of variation between replicates

  • Test across different lots of antibody if possible

By systematically addressing these validation steps, researchers can ensure reliable and reproducible results with the Phospho-TEK (Y1108) antibody in their specific experimental context.

How might Phospho-TEK (Y1108) antibody be utilized in emerging single-cell phosphoproteomic approaches?

Phospho-TEK (Y1108) antibody could play an important role in emerging single-cell phosphoproteomic approaches through:

• Mass cytometry (CyTOF) applications:

  • Metal-conjugate the Phospho-TEK (Y1108) antibody for use in CyTOF panels

  • Combine with other phospho-specific antibodies to profile angiogenic signaling at single-cell resolution

  • Correlate TEK phosphorylation with cell surface markers to identify responsive subpopulations

• Imaging mass cytometry:

  • Apply metal-labeled Phospho-TEK (Y1108) antibody to tissue sections

  • Map spatial distributions of TEK activation in relation to tissue architecture

  • Correlate with other signaling events in the tissue microenvironment

• Single-cell Western blotting:

  • Adapt Phospho-TEK (Y1108) antibody protocols for microfluidic single-cell Western platforms

  • Analyze cell-to-cell variability in TEK activation

  • Correlate with total TEK expression at single-cell level

• Phospho-flow cytometry:

  • Optimize Phospho-TEK (Y1108) antibody for intracellular flow cytometry

  • Develop multi-parameter panels to simultaneously assess multiple signaling nodes

  • Perform high-throughput screening of cell populations

• Integration with computational approaches:

  • Use PhosR or similar tools to analyze single-cell phosphoproteomic data

  • Create computational frameworks that integrate single-cell TEK phosphorylation data with other omics datasets

  • Develop predictive models of cellular heterogeneity in TEK signaling

These approaches would enable unprecedented insights into cellular heterogeneity in TEK signaling dynamics and could reveal new functional subpopulations of cells in angiogenic processes.

What are potential applications of Phospho-TEK (Y1108) antibody in studying vascular pathologies?

Potential applications of Phospho-TEK (Y1108) antibody in studying vascular pathologies include:

• Tumor angiogenesis research:

  • Assess TEK activation patterns in tumor vasculature compared to normal vessels

  • Correlate Y1108 phosphorylation with tumor vessel abnormality and function

  • Monitor changes in TEK activation during anti-angiogenic therapy

  • Identify potential biomarkers for treatment response

• Diabetic vascular complications:

  • Examine TEK phosphorylation status in diabetic retinopathy

  • Investigate altered angiopoietin-Tie2 signaling in diabetic nephropathy

  • Study the impact of hyperglycemia on Y1108 phosphorylation kinetics

  • Assess potential therapeutic approaches targeting TEK signaling

• Cardiovascular disease:

  • Analyze TEK activation in atherosclerotic plaques

  • Study TEK phosphorylation in arterial remodeling after injury

  • Investigate Y1108 phosphorylation in endothelial dysfunction states

  • Explore TEK signaling in heart failure-associated vascular changes

• Inflammatory vascular disorders:

  • Examine TEK phosphorylation in vasculitis

  • Study the role of Y1108 phosphorylation in vascular leak syndromes

  • Investigate TEK activation in inflammatory bowel disease vasculopathy

  • Analyze the effects of anti-inflammatory therapies on TEK signaling

• Therapeutic development applications:

  • Screen candidate compounds for effects on TEK Y1108 phosphorylation

  • Monitor target engagement for TEK-directed therapeutics

  • Develop companion diagnostics for angiopoietin-pathway targeting drugs

  • Identify potential resistance mechanisms to TEK-targeted therapies

These applications could provide valuable insights into disease mechanisms and facilitate the development of novel therapeutic strategies for vascular disorders.

How might phosphoproteomic computational frameworks be optimized for analyzing Phospho-TEK (Y1108) data in complex experimental designs?

Optimizing phosphoproteomic computational frameworks for analyzing Phospho-TEK (Y1108) data in complex experimental designs requires several advanced approaches:

• Enhanced data processing pipelines:

  • Develop specialized filtering algorithms for low-abundance phosphoproteins like TEK

  • Implement site-specific imputation methods that account for biological context

  • Create normalization strategies that preserve biologically meaningful variations

  • Integrate machine learning approaches for improved signal detection

• Contextual analysis frameworks:

  • Design computational methods that integrate Phospho-TEK (Y1108) data with information about cellular microenvironment

  • Develop multi-scale models that connect molecular events to tissue-level phenomena

  • Create algorithms that account for cell-type specific differences in TEK signaling

  • Implement network analysis approaches that position TEK Y1108 phosphorylation within broader signaling networks

• Temporal and spatial modeling:

  • Adapt tools like PhosR to better handle time-series phosphoproteomic data

  • Develop methods for integrating imaging data with phosphoproteomic measurements

  • Create spatiotemporal models of TEK activation dynamics

  • Implement Bayesian frameworks for inferring causal relationships in signaling cascades

• Multi-omics integration strategies:

  • Design computational pipelines that integrate phosphoproteomic data with transcriptomic, metabolomic, and genomic datasets

  • Develop methods for correlating TEK Y1108 phosphorylation with downstream transcriptional programs

  • Create visualization tools that enable intuitive exploration of multi-dimensional datasets

  • Implement systems biology approaches for comprehensive pathway analysis

• Translational bioinformatics approaches:

  • Develop methods for correlating experimental Phospho-TEK (Y1108) data with clinical outcomes

  • Create patient stratification algorithms based on TEK activation profiles

  • Implement drug response prediction models incorporating TEK phosphorylation status

  • Design computational frameworks for identifying optimal combination therapy strategies